Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants and the developing immune system.

Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants and the developing immune system. Expert Rev Gastroenterol Hepatol. 2018 Jul 04;: Authors: Wieringa JW, Driessen GJ, van der Woude CJ Abstract INTRODUCTION: Relapse of Inflammatory Bowel Disease (IBD) during conception and pregnancy has been associated with a negative pregnancy outcome. Therefore, it is advised to maintain drugs in order to prevent relapse. The effect of drugs, which cross the placenta, on children who have been exposed during pregnancy will be discussed in this review. Areas covered: A literature search was performed using the following search terms: inflammatory bowel disease, pregnancy, infant, anti-tumor necrosis factor alpha, infliximab, adalimumab, golimumab, certolizumab, anti-integrins, vedolizumab, anti interleukin 12/23 ustekinumab, placenta, vaccination. Other studies were identified by using references from articles identified through our original literature search. The occurrence of unfavourable pregnancy outcome and congenital malformations does not seem to be increased after exposure to anti-TNFα, but the effects on the developing immune system are largely unknown. For anti-integrins and anti interleukin 12/23, the numbers of exposed pregnancies are to small to draw any conclusions Expert commentary: Follow up of the developing immune system in children exposed to these drugs seems warranted, pr...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research